Dr. Flinn on CAR T-Cell Therapy in Non-Hodgkin Lymphoma

Video

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses chimeric antigen receptor (CAR) T-cell therapy in non-Hodgkin lymphoma (NHL).

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses chimeric antigen receptor (CAR) T-cell therapy in non-Hodgkin lymphoma (NHL).

At the 2018 European Hematology Association Congress, updates were presented on the ZUMA-1 trial. The ZUMA-1 trial examined the use of the anti-CD19 CAR T-cell therapy axicabtagene ciloleucel (KTE-C19; axi-cel) in patients with refractory aggressive NHL. Results were previously published in the New England Journal of Medicine. Axi-cel demonstrated an objective response rate of 82% and a complete response rate of 54% in patients with NHL. Updated results show long-term responses, states Flinn.

Flinn says that the durability of remission was of particular interest, as the fall-off for response typically occurs within the first 3 months of treatment. If patients achieve a complete remission or a partial remission and keep that remission for 3 months, they are likely to maintain that response, explains Flinn.

Recent Videos
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Related Content
© 2025 MJH Life Sciences

All rights reserved.